Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2025)

Historic EBITDA for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$129.5 million.

  • Crinetics Pharmaceuticals' EBITDA fell 7361.66% to -$129.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.9 million, marking a year-over-year decrease of 5379.28%. This contributed to the annual value of -$298.4 million for FY2024, which is 4236.26% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EBITDA is -$129.5 million, which was down 7361.66% from -$116.0 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' EBITDA ranged from a high of -$22.9 million in Q1 2021 and a low of -$129.5 million during Q3 2025
  • Its 5-year average for EBITDA is -$61.0 million, with a median of -$53.4 million in 2023.
  • In the last 5 years, Crinetics Pharmaceuticals' EBITDA crashed by 1453.81% in 2023 and then tumbled by 7361.66% in 2025.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' EBITDA stood at -$31.2 million in 2021, then crashed by 40.91% to -$43.9 million in 2022, then plummeted by 32.66% to -$58.3 million in 2023, then crashed by 40.19% to -$81.7 million in 2024, then plummeted by 58.59% to -$129.5 million in 2025.
  • Its EBITDA stands at -$129.5 million for Q3 2025, versus -$116.0 million for Q2 2025 and -$95.7 million for Q1 2025.